Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to “Hold” Rating by Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities researchers at Royal Bank of Canada from a “moderate buy” rating to a “hold” rating in a research report issued on Friday, Marketbeat reports. They currently have a $662.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective points to a potential upside of 34.21% from the stock’s current price.

A number of other research firms also recently weighed in on REGN. Guggenheim decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating for the company in a research report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Bernstein Bank reduced their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Finally, Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $874.56.

Regeneron Pharmaceuticals Stock Down 18.5%

NASDAQ:REGN traded down $112.15 during trading hours on Friday, hitting $493.24. The stock had a trading volume of 6,307,887 shares, compared to its average volume of 829,478. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 1-year low of $485.00 and a 1-year high of $1,211.20. The business has a 50 day simple moving average of $584.25 and a two-hundred day simple moving average of $667.42. The company has a market cap of $53.25 billion, a PE ratio of 12.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 EPS. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of REGN. Brighton Jones LLC grew its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares in the last quarter. Blue Trust Inc. grew its stake in Regeneron Pharmaceuticals by 39.8% during the 4th quarter. Blue Trust Inc. now owns 724 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 206 shares in the last quarter. First Affirmative Financial Network grew its stake in Regeneron Pharmaceuticals by 28.6% during the 4th quarter. First Affirmative Financial Network now owns 288 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 64 shares in the last quarter. Mediolanum International Funds Ltd grew its stake in Regeneron Pharmaceuticals by 5.3% during the 4th quarter. Mediolanum International Funds Ltd now owns 4,449 shares of the biopharmaceutical company’s stock valued at $3,118,000 after acquiring an additional 224 shares in the last quarter. Finally, AA Financial Advisors LLC grew its stake in Regeneron Pharmaceuticals by 16.1% during the 4th quarter. AA Financial Advisors LLC now owns 448 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.